RecruitingNot ApplicableNCT05540262
Edaravone in the Treatment of Optic Neuritis
Sponsor
First Affiliated Hospital of Guangxi Medical University
Enrollment
50 participants
Start Date
Jan 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
- Patients with a first episode of optic neuritis in either eye
- First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Exclusion Criteria2
- Myopia over 6 diopters
- Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEdaravone
Edaravone injection 30mg three times a day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05540262
Related Trials
Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected
NCT076232529 locations
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT076236681 location
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
NCT0710099031 locations
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
NCT025213111 location
Efgartigimod for the Treatment of Acute Optic Neuritis
NCT064536942 locations